All News

vaccine,mRNA,Covid,vial

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Jack Cush, MD

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.

Read Article
COVID,vaccinate,injection,green

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Jack Cush, MD

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Jack Cush, MD

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:

Read Article
mediterraneansandwich-498379__180.jpg

Dietary Improvement in Psoriatic Arthritis

Jack Cush, MD

The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.  

Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD). https://t.co/sqsOHGThzV https://t.co/zeZrlDeQ9Z

Links:

Dr. John Cush RheumNow ( View Tweet)
One centers experience with a combined Rheum-Derm Clinic. Among 151 psoriasis patients with suspicious musculoskeletal complaints, 85% were dx w/ PsA - 62% of these PsA was 1st diagnosed. https://t.co/RcQrWaXTWj

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - PsA lessons and cases from the Rheumatology clinic. Distinguishing Psoriatic arthritis from Erosive Osteoarthritis can be difficult https://t.co/UCcCMqUL2d https://t.co/zLkfBYI4Cm

Links:

Dr. John Cush RheumNow ( View Tweet)
Mark your calendars for our next Tuesday Night Rheumatology on 4/26 at 7pm! Speakers will include: Dr. Eric Ruderman Dr. Arthur Kavanaugh Dr. David Liew Dr. Jack Cush https://t.co/by1xtmPSZ0 You can also find us LIVE on YouTube, Twitter, and Facebook. https://t.co/o633KHx81b

Links:

Dr. John Cush RheumNow ( View Tweet)
QD clinic - PsA Lessons from Patients Enthesitis in a 14 yr.old - management and evolutionary possibilities https://t.co/MtgoDXJ7EF https://t.co/sTFyySF4vl

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you missed this past Tuesday Night Rheumatology? We have the playback available now. The PsA Expert panelists included: Dr. Dafna Gladman Dr. Joseph Merola, Dr. Peter Nash, Dr. Christopher Ritchlin, Dr. Jose Scher and Dr. Jack Cush. https://t.co/u5lt2uDoGK https://t.co/lOmN4OoGLi

Links:

Dr. John Cush RheumNow ( View Tweet)
Download our newest set of slides on severe Psoriasis. https://t.co/2j5Sp5IAgp https://t.co/QWUFcuu219

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic What are the Safe Treatment Options for psoriatics who have HIV? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fh00ydSYd3 https://t.co/fpDl2tF4cw

Links:

Dr. John Cush RheumNow ( View Tweet)
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for Tuesday Night Rheumatology today! Join us as we discuss the controversies in PsA when it comes to diagnosis, treatment strategies, therapeutics and more. https://t.co/YXAmzvPfeK https://t.co/jtSd0Ig5IT

Links:

Dr. John Cush RheumNow ( View Tweet)
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTX https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×